[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire Vaudois\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":701},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,50,64,97,130,160,189,216,242,261,289,308,333,362,390,425,449,476,498,528,554,583,615,641,670],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644256","prevention-of-rebound-pain-after-orthopaedic-surgery-with-peripheral-nerve-block-reboundpart-a-100644256",false,"NCT07666971","Prevention of Rebound Pain After Orthopaedic Surgery With Peripheral Nerve Block (REBOUND)_part A","Prevention of Rebound Pain After Orthopaedic Surgery With Peripheral Nerve Block: a Single-blinded Randomised Controlled Trial","REBOUND","Inclusion Criteria:\n\n* Patients scheduled for elective orthopaedic surgery on the upper limb\n* Patients scheduled for elective orthopaedic surgery on the lower limb.\n* Score ASA I-III; Patients aged over 18 years; Signed informed consent.\n* Surgery under general anaesthesia or under sedation\n\nExclusion Criteria:\n\n* Refusal or inability to understand the informed consent\n* Allergy to any of the following medications: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine,sufentanil, ondansetron, or dexamethasone\n* Patients with long term opioid treatment\n* Bleeding diathesis\n* Neurological disorders of the operated limb\n* Known renal insufficiency (eGFR \\\u003C30 mL\u002Fmin)\n* Known hepatic insufficiency (Child-Pugh class B or C);\n* Pregnant or breastfeeding women;\n* Alcohol dependence syndrome;\n* Patients under spinal anaesthesia;\n* Patients undergoing amputation procedures","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Rebound pain after peripheral nerve blocks reduces the benefits of regional anesthesia and increases opioid consumption. This rebound pain most likely results from suboptimal pain management, as patients receiving a peripheral nerve block are typically not given scheduled opioid doses. Oral Patient Controlled Analgesia (PCA) consists of an oral morphine prescription that allows patients to self-administer doses based on their pain score.\n\nThis study will compare patients undergoing elective orthopaedic surgery under general anaesthesia or sedation with a peripheral nerve block, receiving oral morphine PCA either with or without additional scheduled oral morphine doses.",[28,29,30],"Post Operative Analgesia","Rebound Pain","Post Operative Pain, Acute",[32,33,34,35,36],"rebound pain","postoperative pain","pain management","orthopaedic surgery","peripheral nerve block","NOT_YET_RECRUITING","2026-06-19",{"date":40,"type":41},"2026-06-24","ACTUAL",{"date":43,"type":22},"2026-06",{"date":45,"type":22},"2027-09",{"name":47,"class":48},"Centre Hospitalier Universitaire Vaudois","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":26,"conditions":57,"keywords":58,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":63,"locationsCount":49},"100644261","prevention-of-rebound-pain-after-orthopaedic-surgery-with-peripheral-nerve-block-reboundpart-b-100644261","NCT07666009","Prevention of Rebound Pain After Orthopaedic Surgery With Peripheral Nerve Block (REBOUND)_part B",{"count":21,"type":22},[25],[28,29,30],[32,33,34,35,36],"2026-06-18",{"date":40,"type":41},{"date":43,"type":22},{"date":45,"type":22},{"name":47,"class":48},{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100584471","phase-1-ny-eso-1-redirected-t-cells-in-patients-with-advanced-melanoma-and-sarcoma-100584471","NCT06889766","NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma","A Phase I Study Evaluating Safety and Feasibility of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 (LauT-1) in Patients With Advanced Melanoma and Sarcoma","LauT1","Inclusion criteria at pre-screening\n\n1\\) Patients with histologically confirmed advanced or metastatic cutaneous melanoma or any type of sarcoma.\n\nInclusion criteria at screening\n\n1. Patients with sarcoma, who have received at least one line of standard therapy (if available) and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.\n2. Patients with metastatic melanoma:\n\n   1. Without proto-oncogene B-Raf (BRAF) mutation who have received at least one line of standard therapy and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.\n   2. With BRAF mutation who have received at least two lines of standard therapy and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.\n3. Patient must have immunohistochemically documented NY-ESO-1 expression, defined as ≥ 1+ expression on either archival or fresh tumor tissue by immunohistochemistry, in ≥50% of the sampled tumor tissue AND HLA-A\\*0201 and\u002For HLA-A\\*0205 positive, as identified by high-resolution genomic deoxyribonucleic acid (DNA) typing of the HLA-A locus.\n4. Age ≥ 18 years\n5. Able to undergo apheresis\n6. At least one lesion accessible to biopsy for translational research (TR) at D30, without putting the patient at unusual risk.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n8. Life expectancy of greater than 12 weeks.\n9. Radiologically measurable disease (as per RECIST v1.1).\n10. Adequate organ function\n\nExclusion Criteria:\n\n1. Patients with an active second malignancy\n2. Patients with symptomatic and\u002For untreated brain metastases, as well as leptomeningeal carcinomatosis. Patients with definitively treated brain metastases will be considered for enrolment after agreement with the Principal Investigator, as long as lesions are stable, there are no new brain lesions, and the patient does not require chronic corticosteroid treatment.\n3. History of idiopathic pulmonary fibrosis or evidence of active pneumonitis (any origin). History of radiation pneumonitis in the radiation field (fibrosis) is allowed.\n4. History of recent myocardial infarction, or unstable angina, within six months prior to enrolment\n5. Patients with prior allogeneic stem cell transplantation or organ transplantation\n6. Active severe systemic infections within 2 weeks prior to apheresis\n7. Patient requiring regular systemic immunosuppressive therapy. All immunosuppressive medications including but not limited to steroids, mycophenolate mofetil, azathioprine, methotrexate, thalidomide, and anti-Tumor Necrosis Factor-alpha (TNF-alpha) agents must have been discontinued at least 2 weeks before apheresis .\n8. History of severe immediate hypersensitivity reaction to any of the agents\u002F excipients of the study products.\n9. Women who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.\n10. Subjects, for whom there are concerns that they will not reliably comply with the requirements for contraception, should not be enrolled into the study.\n11. Any serious underlying medical condition that could interfere with study medication and potential adverse events.",{"count":73,"type":22},9,[75],"PHASE1","A single center, dose escalaion, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous \"New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with non-myeloablative (NMA) lymphodepleting chemotherapy and low dose irradiation (LDI) in patients with NY-ESO-1 positive sarcoma and melanoma.",[78,79,80],"Advanced Melanoma","Melanoma Metastatic","Sarcoma",[82,83,84,85,80,86],"NY-ESO-1","LauT-1","TCR redirected T cell","metastatic melanoma","autolog T-cell","RECRUITING","2026-05-12",{"date":90,"type":41},"2026-05-15",{"date":92,"type":41},"2025-03-24",{"date":94,"type":22},"2029-06",{"name":47,"class":48},2,{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":18,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100635726","effective-of-early-treatment-of-insomnia-on-the-adherence-of-cpap-100635726","NCT07556432","Effective of Early Treatment of Insomnia on the Adherence of CPAP","Comorbid Insomnia and Sleep Apnea (COMISA): Can Early Treatment of Insomnia Improve Adherence to CPAP Therapy?","CoPAP","Inclusion criteria:\n\n1. 45-65 years of age\n2. Diagnosis of OSAS by respiratory polygraphy or polysomnography with an apnea-hypopnea index (AHI) ≥20 when scored by PSG or ≥15 when scored by PG30 with a prescription for CPAP therapy\n3. Diagnosis of chronic insomnia according to the International Classification of Sleep Disorders (ICSD 3-TR).31\n4. Ability to communicate in French\n5. Ability to provide informed consent\n6. Accept to receive information about incidental findings\n7. Ownership of a smartphone running at least Android 9 (API version 28+) or iOS 12.2+.\n\nExclusion criteria:\n\n1. Current treatment for OSAS\n2. Current or past treatment for chronic insomnia (CBT-I)\n3. Severe restless legs syndrome\n4. REM sleep behaviour disorder\n5. Neurological diseases (stroke, Parkinson's disease, etc.)\n6. Severe hypertension (≥180 mmHg systolic or requiring ≥3 antihypertensive medications)\n7. Respiratory failure (oxygen saturation during wakefulness \\\u003C90%)\n8. Severe heart failure (NYHA class III-IV)\n9. High-risk alcohol consumption (≥14 units\u002Fweek)\n10. Known pregnancy\n11. Epilepsy or history of epileptic seizures (ICD-11: 8A6; ICD-10: G40)\n12. Known bipolar disorder of any type (ICD-11: 6A60, 6A61, 6A6Y, 6A6Z; ICD-10: F31)\n13. Known Acute and transient psychotic disorder (ICD-11: 6A23; ICD-10: F23)\n14. Known Active suicidal ideation\n15. Known or suspected severe parasomnias incompatible with programme use (e.g., sleepwalking:\n16. Known Severe cardiovascular disease that may contraindicate unsupervised CBT-I strategies (e.g., unstable arrhythmias, angina pectoris)\n17. Any medical or psychiatric condition that, in the investigator's judgment, would contraindicate the use of the CE-marked HelloBetter Insomnie digital device or participation in CBT-I","45 Years","65 Years",{"count":108,"type":22},120,[25],"This study includes patients suffering from both sleep apnea and insomnia. All participants receive treatment with CPAP. Half of the participants additionally receive a digital program to treat insomnia, initiated at the same time as CPAP. The other half follows usual care and will be able to access the program after 6 months. The aim is to determine whether treating insomnia earlier improves CPAP use and overall health.",[112,113],"Obstructive Sleep Apnea (OSA)","Insomnia Chronic",[115,116,117,118,119,120,121],"Obstructive sleep apnea","OSA","CPAP","COMISA","cognitve behavorial therapy for insomnia","cognitive health","cardiovascular health","2026-04-22",{"date":124,"type":41},"2026-04-29",{"date":126,"type":22},"2026-06-01",{"date":128,"type":22},"2028-12-31",{"name":47,"class":48},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":96},"100632807","phase-2-prospective-clinical-study-to-identify-secondary-sentinel-lymph-nodes-in-patients-with-n1n2b-oral-cavity-or-hn-skin-cancers-using-patent-blue-v-and-indocyanine-green-dyes-100632807","NCT07518485","Prospective Clinical Study to Identify Secondary Sentinel Lymph Nodes in Patients With N1\u002FN2b Oral Cavity or H&N Skin Cancers Using Patent Blue V and Indocyanine Green Dyes","Prospective Clinical Study to Identify Secondary Sentinel Lymph Nodes in Patients With N1\u002FN2b Oral Cavity or H&N Skin Cancers Using Patent Blue V and Indocyanine Green Dyes (preReDSeL Study)","preReDSeL","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Operable SCC located in the oral cavity or the skin of the H\\&N region, with one or two LNM\n3. Primary disease\n4. ECOG performance status 0-2\n5. Signed study informed consent form for participation\n\nExclusion Criteria:\n\n1. Non-operable tumors or contraindication to surgery\n2. Previously treated head and neck cancer. Note: neoadjuvant treatment is not an exclusion criterion\n3. Known hypersensitivity\u002Fallergy to triphenylmethane-based (Blue) dyes or to any of their components\n4. Known hypersensitivity\u002Fallergy to indocyanine green or sodium iodide or iodine\n5. Patients with known hyperthyroidism, thyroid autonomy (e.g., autonomous adenoma), or any thyroid disorder that may lead to increased iodine uptake\n6. Patients with severe renal impairment (e.g., estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n7. Patients receiving beta-blocker therapy, as these medications may mask or reduce the response to anaphylactic reactions induced by dye injection\n8. Pregnancy and\u002For ongoing breastfeeding\n9. Any reason that would interfere with the patient's well-being and treatment as assessed by the investigator",{"count":139,"type":22},20,[141],"PHASE2","Head and neck (H\\&N) cancer has a poor prognosis and high morbidity with \\~50% survival and frequent treatment resistance. Most deaths result from local or loco-regional progression rather than distant metastasis. Lymphatic spread to regional lymph nodes (RLNs), especially with extra-nodal extension (ENE), is a key predictor of poor outcomes. Current imaging techniques often miss micrometastases, leading to extensive but sometimes unnecessary neck treatments. Sentinel lymph node biopsy (SLNB) offers a precise method to detect early spread but is not yet widely adopted. Identifying second-echelon sentinel nodes-those receiving drainage from primary or first-tier nodes-may further refine treatment. The preReDSeL study evaluates the use of dyes (indocyanine green and Patent Blue V) for detecting these nodes. Success could reduce morbidity and guide tailored surgical\u002Fradiation therapy. The follow-up ReDSeL study will assess the clinical value of these findings.",[144,145],"N1\u002FN2b Oral Cavity Cancer","Head and Neck Skin Cancer",[147,148,149,150,151],"oral cavity cancer","head and neck skin cancer","patent blue V","indocyanine green","secondary sentinel lymph nodes","2026-04-07",{"date":154,"type":41},"2026-04-08",{"date":156,"type":22},"2026-04",{"date":158,"type":22},"2027-04",{"name":47,"class":48},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":168,"minAge":4,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":179,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":188,"locationsCount":49},"100570371","compared-reversed-us-guided-dorsal-penile-nerve-block-rusdpnb-with-dpnb-in-circumcisions-for-pediatric-patients-100570371","NCT06706375","Compared Reversed US-Guided Dorsal Penile Nerve Block (RUSDPNB) With DPNB in Circumcisions for Pediatric Patients","A Comparison of Reversed-Ultrasound-Guided Dorsal Penile Nerve Block (RUS-DPBP) and DPNB in Circumcisions for Pediatric Patients","CIRCUSPRO","Inclusion Criteria:\n\n* male\n* undergoing circumcision\n* informed consent\n\nExclusion Criteria:\n\n* other surgery than circumcision in the same time\n* contraindication to local anesthesia\n* allergy to bupivacaine\n* chronic opiates treatment","MALE","17 Years",{"count":171,"type":22},216,[25],"Circumcision is a widely performed surgical procedure. For this reason, optimal analgesic management is essential. Loco-regional anesthesia, particularly penile blocks, combined with general anesthesia is the technique of choice for managing analgesia during circumcisions.\n\nUltrasound is increasingly used in locoregional anesthesia techniques. There is already human research on penile blocks and the use of ultrasound. Studies carried out to date describe an optimization of pain relief in children after circumcision compared with the alternative technique without ultrasound, as well as a reduction in local complications due to injection. However, other studies tend to contradict these findings.\n\nIn order to provide additional knowledge and to verify whether ultrasound could provide with more optimal relief after your circumcision, the investigators are carrying out this study.\n\nThe investigators are proposing to every patient aged 0 to under 18 who is going to undergo circumcision to take part in this project. A letter is sent to all potential participants no later than 3 days before the operation. Consent can be signed no later than the day of the operation. The cooling-off period is the same regardless of age.\n\nTaking part in the study does not affect the operation in any way. The block will take place in the operating room, prior to surgery.\n\nIn this study, participants are randomized into groups. This method is important for obtaining reliable results.\n\n* Group 1 (intervention group): The penile block will be performed using ultrasound.\n* Group 2 (control group): The penile block will be performed using anatomical landmarks.\n\nThis is a \"single-blind\" study, which means that only the anaesthetists, investigators and operating room team will be aware of the allocation to one of the two groups.\n\nData on opiate consumption will be registered as well as the different durations preoperatively, intraoperatively, postoperatively, back in the recovery room and before returning home or any complications as well as pain assessment.",[175,176,177,178],"Circumcision","Ultrasound","Opioid Consumption","Penile Surgery",[180,181],"circumcision","reversed ultrasound guided dorsal penile nerve block","2026-03-24",{"date":184,"type":41},"2026-03-27",{"date":186,"type":41},"2024-11-29",{"date":45,"type":22},{"name":47,"class":48},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":197,"sex":18,"minAge":19,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":96},"100560480","smartphone-blood-pressure-measurement-to-screen-for-hypertension-100560480","NCT06577688","Smartphone Blood Pressure Measurement to Screen for Hypertension","Assessing the Feasibility of Classifying People Using a Machine-learning Approached Based on Features Derived From Smartphone Video Data Recorded at the Person's Fingertip","Optiscreen","Inclusion Criteria:\n\n* Informed consent as documented by signature\n* Men or women older than 18 years old\n* Good understanding of written and oral speaking used at the center where the study will be carried out\n\nExclusion Criteria:\n\n* Patients that cannot sign informed consent\n* Patients in emergency situation, are not legally competent, cannot understand the situation or are vulnerable\n* Unable to participate due to pain or stress \\[12\\]\n* Known or suspected non-compliance (e.g. drug or alcohol abuse, language problems, psychological disorders, dementia)\n* Patients older than 80 years old \\[4\\] \\[13\\]\n* Known pregnancy\n* Known unstable cardiac condition (myocardial infarction \\\u003C 1 week, decompensated heart failure, pulmonary embolism)\n* End-stage renal disease (GFR \\\u003C 15\u002Fmin\u002F1.73m2 and\u002For dialysis) \\[4\\] \\[14\\] \\[15\\] \\[16\\]\n* Diabetes mellitus \\[15\\] \\[8\\]\n* Known (or assessed by recording heart rate and using pulse palpation, as recommended in ESC\u002FESH guidelines \\[1\\]) cardiac arrhythmia (atrial fibrillation, numerous extrasystoles and important bradycardia\u002Fbradyarrhythmia, bigeminy, trigeminy, isolated VPB) \\[4\\] \\[1\\] \\[7\\] \\[15\\] \\[17\\]\n* SBP or DBP difference between two arms \\>10 mmHg \\[8\\] \\[18\\]\n* Patient with finger lesions that would alter the correct capture of signals by the mobile phone.\n* Known mobile phone contact dermatitis (caused by metal allergens, notably nickel and chromium\n* Incapacity of properly using the smartphone (i.e. incapacity of obtaining a recording with sufficient signal quality after the dedicated training)",true,"80 Years",{"count":21,"type":22},"OBSERVATIONAL","The goal of this observational study is to assess the feasibility of classifying people whose blood pressures are within hypertensive range using a machine-learning approach based on features derived from smartphone video data recorded at the patient's fingertips. The main question\\[s\\] it aims to answer are:\n\nIs a smartphone a reliable device for high blood pressure screening ? Is a smartphone a reliable device for blood pressure monitoring ? Participants will record their blood pressure with a smartphone at their fingertips and with an approved cuff device, 3 times in the morning and 3 times in the evening for 7 days. There will be two groups, a volunteer presumed healthy, and a volunteer addressed for a Home Blood pressure monitoring with the diagnosis of hypertension suspected.\n\nResearchers will compare the two groups to see if the smartphone can be reliable in terms of diagnosis and monitoring of the blood pressure comparing to a standard cuff device.",[203,204],"Blood Pressure","Blood Pressure Disorders",[206,207,208,209],"blood pressure","smartphone","Home blood pressure monitoring","Blood pressure disorders screening",{"date":184,"type":41},{"date":212,"type":41},"2024-09-01",{"date":214,"type":22},"2026-12-30",{"name":47,"class":48},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":227,"conditions":228,"keywords":232,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":49},"100550933","predisuisse-automatized-assessment-of-difficult-airway-100550933","NCT06453525","PrediSuisse: Automatized Assessment of Difficult Airway","PrediSuisse: Automatized Assessment of Difficult Airway Using Three Videolaryngoscopes With the Help of Facial Recognition Techniques and Neural Network","PrediSuisse","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old) presenting at the pre-anesthesia consult for an elective general anesthesia necessitating a tracheal intubation\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients not speaking French (in Geneva and Lausanne) or Italian (in Lugano).\n* Patients previously operated on the airway with anatomical modifications (ENT Flaps, tracheotomies).\n* Patients unable to follow procedures or to give consent will also be excluded.","100 Years",{"count":226,"type":22},1800,"In the \"PrediSuisse\" research project, the investigators aim to create a reliable, reproducible, ultra-portable and radiation-free automatized software, able to identify automatically collected features, facial characteristics, and range of movements, to predict intubation difficulty. The software will generate a difficulty intubation score tailored to three commercially available videolaryngoscopes with different type of blades, corresponding to the predicted endotracheal intubation difficulty while providing the anaesthesiologist a reliable and non-subjective tool to assess individual patient's risks with regards to airway management.",[229,230,231],"Anesthesia","Intubation; Difficult or Failed","Airway Complication of Anesthesia",[233,234,235],"Intubation","difficult airway","videolaryngoscopy",{"date":184,"type":41},{"date":238,"type":41},"2025-01-01",{"date":240,"type":22},"2027-01-31",{"name":47,"class":48},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":49},"100528074","perioperative-smart-device-monitoring-to-predict-complications-100528074","NCT06156033","Perioperative Smart Device Monitoring to Predict Complications","Perioperative Smart Device Monitoring as a Tool to Predict Post-operative Complications in Patients Undergoing Non Cardiac Intermediate and High-risk Surgery. A Single-center Prospective Observational Study","PreSmart","Patients will be recruited prospectively for a total of 50 patients.\n\nInclusion criteria are :\n\n* Patients scheduled for elective non cardiac intermediate or high-risk surgery under general anesthesia\n* 18 years of age or older\n* Capacity to understand french language\n\nExclusion criteria will be :\n\n\\- Patient refusal and\u002For inability to understand and sign informed consent",{"count":251,"type":22},50,"This is a prospective, single-center, observational study designed to to quantify complications following non cardiac intermediate and high-risk surgery, and to identify digital biomarkers (collected pre, and post-operatively by a connected device) enabling early early identification of patients with post-operative complications. Patients will be invited to wear a smartdevice during the perioperative period, and will receive questionnaires about their their health status.",[254],"Post-Op Complication",{"date":184,"type":41},{"date":257,"type":22},"2026-04-01",{"date":259,"type":22},"2027-03",{"name":47,"class":48},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":18,"minAge":268,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":278,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":96},"100489352","study-comparing-two-methods-for-the-treatment-of-large-chondral-and-osteochondral-defects-of-the-knee-100489352","NCT05651997","Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee","Randomized Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee: Augmented Microfracture Technique vs. 3rd Generation of ACI","Inclusion Criteria:\n\n* Patients aged between 15-50 years\n* Symptomatic chondral and osteochondral defect, grade III and IV according to the ICRS classification, and size between 2.5 and 15 cm2\n* Failure of a conservative treatment\n* Patient in good general condition, documented by an ASA score ≤ 2 (American Society of Anesthesiologists)\n* Patient considered compliant and able to participate in rehabilitation and pre- and post-operative follow-up\n* Consent to participate in the study\n\nExclusion Criteria:\n\n* All inflammatory and synovial pathologies\n* Diffuse or mirror lesions\n* An unfavorable biomechanical environment\n* Obesity grade II or higher, with a BMI\\>35 kg\u002Fm2\n* Active smoking\u002F active drug dependency (hard drugs)\n* Poor compliance\n* The patient is already part of another clinical trial that may compromise the present study\n* Vulnerable populations (except minors aged 15-18 years)\n* Presence of open growth plate (15-18 years)\n* Pregnancy or planned pregnancy during the study (MRI-related contra-indication)\n* Proven allergy to penicillin and gentamicin (for MACT group) and porcine collagen (for both groups)\n\nFor final inclusion, an additional exclusion criteria will be assessed after randomization:\n\n\\- Positive to HIV, HBV, HCV, syphilis.","15 Years","50 Years",{"count":271,"type":22},80,[25],"The major objective of this study is to evaluate the efficacy of the MACT versus the AMT for the treatment of large cartilage defects in patellofemoral and femorotibial injuries.",[275,276,277],"Articular Cartilage Defect","Chondral Defect","Osteochondritis",[279,280],"Cellular therapy","Human articular chondrocytes","2026-03-10",{"date":283,"type":41},"2026-03-12",{"date":285,"type":22},"2026-12",{"date":287,"type":22},"2032-06-01",{"name":47,"class":48},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":268,"maxAge":269,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":49},"100385267","introduction-of-aci-for-cartilage-repair-100385267","NCT04296487","Introduction of ACI for Cartilage Repair","Introduction of Autologous Chondrocyte Implantation Procedure for the Treatment of Chondral Defect in the Knee","Inclusion Criteria:\n\n1. Age between 15 and 50.\n2. Lesions classified as ICRS Grade III or IV and smaller than 15 cm2\n3. Lesions that have failed prior therapy (conservative or surgical treatment ≥ six months)\n4. Subjects who understand and sign the consent form for this study\n\nExclusion Criteria:\n\n1. Body mass index (BMI) of 35 or more\n2. Osteoarthritis or rheumatoid arthritis\n3. Diffuse lesion\n4. Uncorrected mal-alignment, ligamentous instability, or meniscal tear\n5. Presence of growth cartilage (15-18 years old)\n6. Active smoking or drug consumption\n7. Women who are pregnant\n8. Positive serology for HIV-1 or HIV-2, Hepatitis B and C and syphilis\n9. Proven allergy to porcine collagen, penicillin and gentamicin\n10. Poor compliance",{"count":297,"type":22},218,[25],"This study was aimed to evaluate effectiveness and safety of autologous chondrocyte suspension for treatment of knee articular cartilage defects.",[275,276,277],{"date":302,"type":41},"2026-03-11",{"date":304,"type":41},"2017-09-01",{"date":306,"type":22},"2030-09",{"name":47,"class":48},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":332},"100625813","swissneurorehab---hdhi-100625813","NCT07427511","SwissNeuroRehab - HDHI","SwissNeuroRehab - High Dose High Intensity Neurorehabilitation Along the Continuum of Care","SNR-HDHI","Inclusion Criteria:\n\n* Adults aged 18-85 years.\n* Confirmed diagnosis of stroke (ischemic or hemorrhagic) \\>7 days ago\n* Be able to sit unassisted\n* Able and willing to give informed consent\n* Have motor difficulties of the Upper Extremity and\u002For Lower Extremity\n* Willing to commit to program length \\& daily training dose\n* Willing to have assessments at start and end of program\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severe cognitive impairment\n* Uncontrolled seizure disorder or epilepsy - clinician's judgement)\n* Any medical condition that would compromise their safety (inability to communicate, vision or hearing impairment, heart condition that limits participation in exercise) and tolerability (cardiac contraindications)\n* Pain that would limit rehabilitation dose\n* Severe apraxia\n* Severe memory disorder\n* Severe hemispatial neglect\n* Plegia of the affected limb","85 Years",{"count":108,"type":22},[25],"High-dose, high-intensity (HDHI) neurorehabilitation has shown promise for improving functional outcomes after acquired brain injury (ABI), yet its feasibility and impact across different stages of care and real-world clinical settings remain insufficiently understood.\n\nThe SwissNeuroRehab (SNR) initiative, bringing together Swiss rehabilitation centres to develop and evaluate innovative, technology-supported models of neurorehabilitation, provides the broader framework within which this study is conducted.\n\nWithin this framework, a structured HDHI therapy pathway supported by CE-marked digital neurorehabilitation tools has been developed for delivery across inpatient, outpatient, and home environments in Switzerland.\n\nThis multicentre, non-randomised interventional feasibility study evaluates the feasibility and preliminary clinical effects of implementing this HDHI rehabilitation pathway for adults with stroke in subacute and chronic stages. Participants will receive approximately 300 minutes per week of active, technology-supported training in addition to standard rehabilitation care, following an individually tailored pathway across settings. Standardised clinical assessments, patient-reported outcomes, documentation of rehabilitation procedures, and socioeconomic measures will be collected at baseline, discharge, and follow-up timepoints up to 12-15 months post-enrollment.\n\nThe primary aim of the study is to assess the feasibility of the HDHI intervention within routine rehabilitation workflows across multiple Swiss centres. Feasibility will be evaluated through (i) adherence to at least half of the weekly 300-minute Active Training Time target and (ii) patients' perceived feasibility and satisfaction with the program.\n\nSecondary aims are to explore preliminary clinical and functional changes, patient-reported outcomes, and quantify socioeconomic impacts through dedicated surveys and cost data.\n\nFindings from this study will (i) determine whether a structured HDHI rehabilitation pathway can be feasibly implemented across diverse clinical contexts, (ii) provide initial estimates of clinical and socioeconomic outcomes to support planning of future controlled trials.",[321],"Stroke",[323,324],"high dose","intensive therapy","2026-03-06",{"date":281,"type":41},{"date":328,"type":22},"2026-02-10",{"date":330,"type":22},"2028-05-31",{"name":47,"class":48},5,{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":348,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":361},"100613196","phase-2-efficacy-of-the-combination-of-trimipramine-and-atezolizumab-with-bevacizumab-in-patients-with-recurrent-glioblastoma-a-phase-2-trial-100613196","NCT07263438","Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial","Open-label Phase II Clinical Trial to Test the Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma","Phenix","Inclusion Criteria:\n\n* Histologically or cytologically confirmed glioblastoma, according to World Health Organization \\[WHO\\] 2021 with unequivocal first progression after standard (6 weeks radiotherapy \\[RT\\]) with concurrent \\& adjuvant temozolomide \\[TMZ\\] chemotherapy.\n* Patients must be at least 3 months off the concomitant part of chemo-radiotherapy.\n* Stable or decreasing dose of steroids for 7 days prior to the baseline\n* Magnetic Resonance Imaging \\[MRI\\] scan.\n* Maximum dose of dexamethasone (or equivalent) 4 mg at time of inclusion.\n* No surgery or other invasive procedures (major surgical procedure, open biopsy or significant traumatic injury) within 4 weeks prior to registration.\n* No core biopsy or other minor surgical procedure within 7 days prior to registration. (Placement of a central vascular access device, if performed at least 2 days prior to trial treatment administration, is allowed).\n* Patients who require anti-convulsant therapy must be taking non-enzyme inducing antiepileptic drugs \\[non-EIAED\\]. Patients previously on EIAED must be switched to non-EIAED at least 2 weeks prior to registration.\n* Measurable disease per Response Assessment in Neuro-Oncology \\[RANO\\] version 2.0 criteria. Recurrent disease must be at least one bi-dimensionally measurable contrast-enhancing lesion with clearly defined margins by MRI scan, with minimal diameters of 10 mm, visible on 2 or more axial slices 5 mm apart, based on MRI scan done within 28 days prior to registration.\n* Karnofsky performance status 70-100.\n* Adequate bone marrow function: neutrophil count ≥ 1.5 x 10\\^9\u002FL, platelet count ≥ 100 x 109\u002FL, hemoglobin ≥ 90 g\u002FL.\n* Adequate hepatic function: total bilirubin ≤ 1.5 x Upper Limit of Normal \\[ULN\\] (except for patients with Gilbert's syndrome ≤ 3.0 x ULN), aspartate aminotransferase \\[AST\\] and alanine transaminase \\[ALT\\] and alkaline phosphatase \\[AP\\] ≤ 2.5 x ULN.\n* Adequate renal function: estimated glomerular filtration rate \\[eGFR\\] ≥ 45 mL\u002Fmin\u002F1.73 m2 (according to Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] formula).\n* Urine dipstick for proteinuria \\\u003C 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein\u002F24 hours.\n* Adequate coagulation function: International Normalized Ratio \\[INR\\] ≤ 1.5 x ULN (the ULN for INR is defined with the value 1.2 for all sites, in case no ULN is documented in the laboratory certificates\u002Fsheets). Use of full-dose anticoagulants is permitted as long as the INR is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks before registration, as per American Society for Clinical Oncology \\[ASCO\\] guidelines, low molecular weight heparin \\[LMWH\\] should be the preferred approach. Concomitant anticoagulation with aspirin (up to 300 mg\u002Fday) and anticoagulation with LMWH is allowed.\n* Women of childbearing potential must use highly effective contraception , are not pregnant or breast-feeding and agree not to become pregnant during trial treatment and until 6 months after the last dose of investigational drug. A negative pregnancy test before inclusion into the trial is required for all women of childbearing potential.\n* Men agree not to donate sperm or to father a child during trial treatment and until 6 months after the last dose of investigational drug.\n* Patient is able and willing to swallow trial drug as whole tablet.\n\nOnly for Cohort 2:\n\n* Consent to giving access of part of the tumor tissue and Cerebrospinal Fluid \\[CSF\\] obtained during the routine neurosurgical procedure for pharmacology and translational studies. Tumor tissue will only be made available once it is established that enough tumor tissue is available for standard neuropathological analysis.\n* Patients that have a medical indication for a neurosurgical resection from first recurrent tumor.\n\nExclusion Criteria:\n\n* Patient must be in first progression\u002Frecurrence and have not received more than one line of chemotherapy (concurrent and adjuvant temozolomide). Treatment of Time to Treatment Failure \\[TTF\\] fields (Optune®) is allowed during first line but will be stopped at registration.\n* Patients must not have prostate enlargement with urinary retention or angle-closure glaucoma at registration.\n* Any other experimental drug must be discontinued at least 30 days prior to registration\n* Patients under ongoing treatment with an antidepressant must be eligible for a switch to trimipramine. Patients currently under TriCyclic Antidepressant \\[TCAs\\] (amitriptyline, clomipramine, nortriptyline, imipramine), selective serotonin reuptake inhibitors (sertraline, paroxetine, fluvoxamine, citalopram, escitalopram) or serotonin and norepinephrine reuptake inhibitors (venlafaxine, duloxetine) must be weaned off these medications for at least 14 days before the introduction of trimipramine.\n\nNote: Patients treated with fluoxetine prior to enrollment will only be eligible for this trial after a two-month washout period before starting the study treatment.\n\n* Prior treatment with atezolizumab or any other immune checkpoint inhibitors.\n* Prior treatment with bevacizumab or other Vascular Endothelial Growth Factor \\[VEGF\\] inhibitors or VEGF-receptor signaling inhibitors.\n* Concomitant or prior use of immunosuppressive medication within 5 half-lives before registration, with the exceptions of intranasal and inhaled corticosteroids.\n* Life expectancy of less than 12 weeks.\n* Active systemic prior malignancy. Patients with a prior malignancy (basal cell carcinoma of the skin, squamous carcinoma of the skin or carcinoma in situ of the cervix) and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration.\n* Blood pressure combination treatment with more than two antihypertensive medications or uncontrolled blood hypertension under properly antihypertensive medications.\n* Severe or uncontrolled cardiovascular disease (congestive heart failure New York Heart Association \\[NYHA\\] III or IV; unstable angina pectoris, history of myocardial infarction within the last six months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).\n* Have a heart rate corrected QT interval using Fridericia's formula \\[QTcF\\] (QTc = QT \u002F RR\\^1\u002F3) ≥ 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events (e.g. heart failure, hypokalaemia, familial history of long QT interval syndrome). Patients with bundle branch block and prolonged QTcF are permitted with approval of the sponsor investigator.\n* Presence of a grade 3 atrioventricular \\[AV\\] block on electrocardiogram \\[ECG\\].\n* History of cerebrovascular accident or intracranial haemorrhage within 6 months prior to registration.\n* Known history of human immunodeficiency virus \\[HIV\\] or active chronic hepatitis C or hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antimicrobial treatment.\n* Known history of tuberculosis, known history of primary immunodeficiency, known history of allogeneic organ transplant. Receipt of live attenuated vaccine within 28 days prior to the first dose of atezolizumab administration. Vaccination with inactivated viruses, such as those in the influenza vaccine, are permitted.\n* History of or active auto-immune disease with the exception of diabetes mellitus type II and well controlled hypothyroidism on treatment.\n* Concomitant treatment with strong or moderate cytochrome P450 3A or 2D6 \\[CYP3A or CYP2D6\\] inducers or inhibitors.\n* Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information.\n* Monoamine oxidase inhibitors \\[MAOI\\] (Rasagiline, or others not approved in Switzerland, such as phenelzine, tranylcypromine, isocarboxazid and selegiline). Of note, MAOI must have been stopped at least 14 days prior to the start of trimipramine.\n* Known hypersensitivity to trial drug(s) or to any component of the trial drug(s)\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient",{"count":342,"type":22},59,[141],"This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not.\n\nThe aim of the cohort 1 (patients without indication for surgery) is to analyze the clinical efficacy of this triple combination in recurrent glioblastoma. 48 patients will be registered.\n\nThe aim of cohort 2 (patients with indication for surgery) is to confirm the level of trimipramine that can be achieved in the tumor tissue and cerebrospinal fluid collected during surgery. At least 5 patients will be registered.\n\nAll patients will receive the combination treatment (trimipramine and atezolizumab associated with bevacizumab) for a maximum period of 2 years from registration. The treatment schedule is slightly different for the 2 cohorts because of the neurosurgical resection foreseen for cohort 2 and the requirement to start bevacizumab only after the surgery. After the end of treatment, all patients will be followed up for safety during 90 days from first treatment administration and then up to 3 years from registration.",[346,347],"Glioblastoma","Recurrence Tumor",[349,350,351,352],"recurrent glioblastoma","trimipramine","atezolizumab","bevacizumab","2026-02-11",{"date":355,"type":41},"2026-02-13",{"date":357,"type":41},"2025-11-03",{"date":359,"type":22},"2030-12-31",{"name":47,"class":48},7,{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":371,"briefSummary":372,"conditions":373,"keywords":379,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":49},"100623165","jafron-cytokine-adsorber-during-pediatric-open-heart-surgeries-100623165","NCT07393087","Jafron Cytokine Adsorber During Pediatric Open-Heart Surgeries","JACKPOT","Inclusion Criteria:\n\n* Children ≤ 10 years old at study inclusion\n* Children weighing at least 5 kg at study inclusion\n* Planned for open-heart cardiac surgery with CPB-time ≥ 120 min and aortic clamping.\n* Informed consent obtained from parent(s)\u002Flegal representative\n\nExclusion Criteria:\n\n* Children having an indication to receive hemoadsorption during CPB for drugs removal or other medically justified reason\n* Previous enrolment into the current study\n* Off-pump procedure\n* Chronic immunosuppression (chronic corticosteroid therapy, chemotherapy, anti-leucocyte drugs, TNF blockers or else)\n* Known allergy to heparin or heparin induced thrombocytopenia.\n* Severe thrombopenia (platelets count before surgery \\\u003C 20G\u002FL)\n* Parent(s)\u002Flegal representative not able to understand\u002Fread French and\u002For English\n* Participation in another conflicting research study","10 Years",{"count":139,"type":22},[25],"This prospective single-center randomized controlled trial aims at evaluating the safety and feasibility of an hemoadsorption protocol using Jafron HA-60 during cardio-pulmonary bypass in 20 pediatric patients undergoing open-heart surgery.",[374,375,376,377,378],"Cardiac Surgery Recovery","Inflammation","Complex Cardiovascular Surgery With Cardiopulmonary Bypass","Cytokine Storm","Pediatric Open Heart Surgery",[380,381,382],"Feasibility pilot study","Pediatric open heart surgery","Hemoadsorption","2026-02-06",{"date":328,"type":41},{"date":386,"type":22},"2026-03",{"date":388,"type":22},"2029-04",{"name":47,"class":48},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":402,"conditions":403,"keywords":411,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":424},"100495100","phase-3-the-role-of-preoperative-immunonutrition-on-morbidity-and-immune-response-after-cystectomy-incyst-trial-100495100","NCT05726786","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial)","INCyst","Inclusion Criteria:\n\n* Patient undergoing open cystectomy (for all reasons)\n* Age ≥18 years\n* Ability and willingness to provide informed consent documented by signature\n\nExclusion Criteria:\n\n* Contraindications to IN, e.g. known hypersensitivity or allergy to lactose, fish oil or soy lecithin\n* Severe diarrhoea requiring medical attention\n* Current treatment with any immunosuppressive drug\n* In standard practice, pregnant or lactating women are systematically rejected by the surgeon for this surgical procedure. Furthermore, during the pre-surgical anaesthesia consultation, the eligibility of each patient for anaesthesia will be assessed according to the usual criteria and recommendations of the anaesthesia service of the CHUV\n* Other clinically significant concomitant disease affecting immunity (e.g., severe renal failure, HIV, SLE, transplant recipient, ...)\n* Inability to follow the procedures of the study, e.g. due psychological disorders, dementia, etc.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Use of IN independently of the study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n* Emergency procedure (less than 7 days between screening and surgery)",{"count":399,"type":22},232,[401],"PHASE3","The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy.\n\nAs a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN.\n\nThis is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.",[404,405,406,407,408,409,410],"Bladder Cancer","Interstitial Cystitis","Painful Bladder Syndrome","Neurogenic Bladder","Hemorrhagic Cystitis","Endometriosis","Bladder Disease",[412,413,414,415],"Cystectomy","Immunonutrition","Complication","Malnutrition","2025-12-02",{"date":418,"type":41},"2025-12-09",{"date":420,"type":41},"2023-04-10",{"date":422,"type":22},"2026-10",{"name":47,"class":48},4,{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":4},"100601353","comparison-of-pericapsular-nerve-group-peng-block-with-a-combined-femoral-sciatic-lateral-femoral-cutaneous-nerve-block-for-postoperative-analgesia-in-secondary-total-hip-arthroplasty-revpet-100601353","NCT07109388","Comparison of Pericapsular Nerve Group (PENG) Block With a Combined Femoral, Sciatic, Lateral Femoral Cutaneous Nerve Block for Postoperative Analgesia in Secondary Total Hip Arthroplasty; (REVPET)","Comparison of Pericapsular Nerve Group (PENG) Block With a Combined Femoral, Sciatic, Lateral Femoral Cutaneous Nerve Block for Postoperative Analgesia in Secondary Total Hip Arthroplasty.","REVPET","Inclusion Criteria:\n\n* Male and female patients\n* ASA (American Society of Anaesthesiologists) I-III\n* 18 years of age or older\n* Patients scheduled for elective secundary hip arthroplasty\n* Able to give written conformed consent autonomously\n\nExclusion Criteria:\n\n* Refusal or inability to give consent\n* Allergy to any of: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine, ondansetron or dexamethasone\n* Bleeding diathesis\n* Neurological deficit of the operative side\n* Existing preoperative opioid use\n* Renal insufficiency (GFR\\\u003C30ml\u002Fmin according to the Cockroft-Gault formula)\n* Hepatic insufficiency\n* Morbid Obésity III",{"count":251,"type":22},[25],"The aim of this clinical trial is to compare the analgesic effect of a pericapsular nerve group (PENG) block with a combined femoral, sciatic, lateral femoral cutaneous nerve block for postoperative analgesia in patients scheduled for secondary total hip arthroplasty. The primary objective of this study is to compare postoperative pain management between the PENG block and the combined block (femoral, sciatic, lateral femoral cutaneous) by measuring postoperative morphine consumption in each of the two groups.\n\nParticipants will be randomized into two groups. Patients assigned to the PENG group will receive a PENG block with ropivacaine, followed by a sham (sciatic) block, and spinal anesthesia with isobaric bupivacaine. Patients assigned to the combined block group will receive femoral, sciatic, lateral femoral cutaneous nerve blocks with ropivacaine, followed by spinal anesthesia with isobaric bupivacaine.",[437,28,30],"Hip Arthroplasty Replacement",[439,33,440],"nerve block","hip arthroplasty replacement","2025-09-16",{"date":443,"type":41},"2025-09-22",{"date":445,"type":22},"2025-09-30",{"date":447,"type":22},"2027-09-01",{"name":47,"class":48},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":197,"sex":18,"minAge":19,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":460,"conditions":461,"keywords":464,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":49},"100603687","deciphering-the-mechanisms-of-central-bp-regulation-in-patients-with-pd-associated-with-orthostatic-hypotension-100603687","NCT07139756","Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension","Deciphering the Mechanisms of Central Blood Pressure Regulation in Patients With Parkinson Disease Associated With Orthostatic Hypotension: A 2-phase Observational Study With Healthy Participants and Patients With Parkinson's Disease","HYPOPARK","Phase 1:\n\nInclusion Criteria:\n\n* Signed informed consent\n* Age ≥ 18 years and \\\u003C75 years\n* Normal office blood pressure (\\\u003C140\u002F90 mmHg)\n* For women of childbearing potential: using or willing to use during the study a reliable contraception method compatible with MRI\n\nExclusion Criteria:\n\n* Schellong test showing OH (drop of Systolic BP \\>20 mmHg or Diastolic BP \\>10 mmHg)\n* Pregnant or lactating women\n* Refusal to be informed of incidental findings\n* Any medication (acute or chronic prescription) except oral contraception\n* Clinical significant abnormal blood test as assessed by the investigator\n* Chronic or acute illness\n* Concomitant participation in a clinical trial\n* Blood donation in the 60 previous days\n* Contra-indications for MRI\n* Unable to follow study procedures\n* Having a hierarchical relationship with the investigator or being family of the investigator\n\nPhase 2:\n\nInclusion Criteria:\n\n* Signed informed consent\n* Fulfilling Movement Disorder Society clinical criteria for \"clinically established PD\"\n* Age ≥18 years and \\\u003C75 years\n* PD treated by dopamine replacement therapy (DRT)\n* Willing and able to comply with the visit schedule and study procedures\n* Autonomous in daily life\n* Schellong test showing OH (drop of Systolic BP \\>20 mmHg or Diastolic BP \\>10 mmHg)(for study group with OH) or no OH (for studygroup without OH)\n* For women of childbearing potential: using or willing to use during the study a reliable contraception method compatible with MRI\n\nExclusion Criteria:\n\n* Unable to give an informed consent\n* BP \\> 180\u002F110 mmHg on 24-hour ambulatory blood pressure monitoring\n* eGFR \\\u003C 45 ml\u002Fmin\u002F1.73 ml\u002Fmin\u002Fm2 by CKD-EPI equation\n* having contra-indications for MRI\n* Pregnant or lactating women\n* Refusal to be informed of incidental findings\n* Allergy to components of contrast agent Sonovue®\n* Living in an institution\n* Dementia\n* Type 2 diabetes\n* Stroke or myocardial infarction in the past 6 months\n* Blood donation in the previous 6 months\n* Active oncology treatment\n* Having a hierarchical relationship with the investigator or being family of the investigator","75 Years",{"count":459,"type":22},130,"Phase 1 objective: test the feasibility of using a 3Tesla MRI scanner instead of a 7Tesla MRI scanner to measure brainstem responses to LBNP in healthy participants.\n\nPhase 2 primary objective: compare the brainstem responses to LBNP in patients with PD associated with OH to PD patients without OH using BOLD fMRI",[462,463],"Parkinson Disease","Orthostatic Hypotension",[465,466,467],"lower body negative pressure","parkinson disease","orthostatic hypotension","2025-08-18",{"date":470,"type":41},"2025-08-24",{"date":472,"type":22},"2025-10-01",{"date":474,"type":22},"2028-03-31",{"name":47,"class":48},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":106,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":49},"100492394","efficacy-of-doll-therapy-in-the-dementia-in-acute-geriatric-inpatients-100492394","NCT05691569","Efficacy of Doll Therapy in the Dementia in Acute Geriatric Inpatients","Efficacy of Doll Therapy in the Control of Behavioral and psychologIcal Symptoms of Dementia in Acute Geriatric Inpatients: the AGITATE Study.","AGITATE","Inclusion Criteria:\n\n* age ≥65 years\n* diagnosis of dementia moderate to severe Clinical Dementia Rating scale (CDR) ≥2\n* presence of agitation and\u002For aggressiveness\n* manual and visual abilities sufficient in order to interact with the doll.\n\nExclusion Criteria:\n\n* age \\\u003C65 years;\n* refuse to participate;\n* mild forms of dementia (CDR\\\u003C2);\n* contraindication for DT as experience of mournful or traumatic events related to parental experience;\n* life expectancy lower than 3 months;\n* infectious diseases requiring isolation;\n* negative interaction with the doll,\n* presence of delirium.",{"count":485,"type":22},92,[25],"Summary. Behavioral and psychological symptoms of dementia (BPSD) represents a huge emotional stress and an important burden for the patients and the caregivers severely reducing their quality of life. BPSD worsen during hospitalization and require the administration of psychotropic drugs that are often insufficient to control the symptoms, and may cause severe adverse events.\n\nThe investigators propose the use of empathy dolls in order to reduce BPSD and in particular agitation and aggressiveness in acute geriatric in-patients affected by moderate to severe forms of dementia.\n\nThe use of doll therapy in the clinical routine will allow to reduce the use of psychotropic drugs, shorten hospitalization, reduce professional and family caregiver burden improving patients' and families' quality of life.",[489],"Dementia","2025-04-07",{"date":492,"type":41},"2025-04-09",{"date":494,"type":41},"2024-11-15",{"date":496,"type":22},"2027-08-30",{"name":47,"class":48},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":514,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":49},"100586103","68ga-fapi-46-in-staging-of-pancreatic-adenocarcinoma-100586103","NCT06911021","68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma","68Ga-FAPI-46 PET\u002FCT for Tumor Fibroblast Imaging to Refine Tumor Assessment and Therapeutic Strategies of Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Age ≥18 years.\n* Karnofsky index ≥80%.\n* Operable or operable borderline tumor after neoadjuvant chemotherapy response\n* Planned surgical tumor resection.\n* SOC imaging (ceCT and MRI) performed as pre-surgery exams.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Claustrophobia.\n* Severe renal insufficiency (GFR\\\u003C30 mL\u002Fmin\u002F1.73m²).\n* Liver enzymes (ALAT, ASAT \\>5× the upper limit).\n* Bilirubin \\>3× the upper limit.\n* Hemoglobin \\\u003C8 g\u002FdL.\n* Absolute neutrophil count \\\u003C1000\u002Fmm³.\n* Platelets \\\u003C75,000\u002FµL.\n* Inability to give informed consent or follow study procedures.\n* The patient refuses to receive information regarding incidental findings.",{"count":139,"type":22},[25],"This clinical study investigates the use of a new imaging technique called 68Ga-FAPI-46 PET\u002FCT in people with pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its rapid progression, late diagnosis, and poor survival rate. One of the main challenges with pancreatic cancer is that standard images like MRI and CT, while helpful, are not always able to clearly show how far the cancer has spread or where exactly the tumor ends. This can make surgery and treatment planning more difficult and less precise.\n\nThe new image technique being studied, 68Ga-FAPI-46 PET\u002FCT, works by injecting a small and safe amount of a radioactive substance into a vein. This substance travels through the body and attaches to a specific protein called FAP, which is found in large amounts in the tissue that surrounds many pancreatic tumors. By sticking to this protein, the tracer highlights not only the tumor but also the surrounding area that may be affected by the cancer. This results in very detailed images that may show the tumor more clearly than other techniques.\n\nEach participant in the study will receive a single injection of the tracer, and about an hour later they will have the PET\u002FCT scan. The scan itself is quick, painless, and non-invasive, and takes about 20 minutes. A few days later, participants will receive a follow-up phone call to check if they experienced any side effects, though previous studies with over 1,000 people have shown the tracer to be very safe.\n\nThe purpose of the study is to find out whether this new technique provides more useful and accurate information than the standard images currently used. It may help better detect the size of the tumor, see if it has spread to other parts of the body, and give doctors a clearer idea of how to plan surgery. This could make it easier to remove the tumor completely and choose the most effective treatment for each patient.\n\nThis pilot study is being conducted at Lausanne University Hospital (CHUV) with 20 adult participants over two years. CHUV is the first hospital in Switzerland to offer this kind of scan. If the study is successful, this scan may become a regular part of care for people with pancreatic cancer and could also be used in other cancers in the future.",[509,510,511,512,513],"Pancreatic Adenocarcinoma","PET \u002F CT","FAPI","Surgical Oncology","Molecular Imaging",[515,516,517,518,519],"Novel imaging in pancreatic cancer","Fibroblast activation protein imaging","Cancer-associated fibroblasts","PET\u002FCT and pancreatic tumor","Tumor microenvironment imaging","2025-03-28",{"date":522,"type":41},"2025-04-04",{"date":524,"type":22},"2025-05-01",{"date":526,"type":22},"2027-12-31",{"name":47,"class":48},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":553,"locationsCount":49},"100506069","phase-2-doac-in-patients-with-child-a-or-b-liver-cirrhosis-100506069","NCT05869591","DOAC in Patients with Child a or B Liver Cirrhosis","Pharmacokinetics and Pharmacodynamics Assessment of Apixaban and Edoxaban in Patients with Child a or B Liver Cirrhosis","CIRROAC","Inclusion Criteria:\n\n* Age 18 years or older\n* Patient with previously diagnosed liver cirrhosis Child A or B\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Oesophageal varices with grade superior to 1 or with red signs\n* Active ulcer disease of the gastrointestinal tract\n* History of haemorrhagic stroke\n* Severe uncontrolled hypertension\n* Recent brain, spinal or ophthalmic surgery\n* Kidney function inadequate for DOAC treatment\n* Concomitant treatment with anti-platelet drugs\n* Concomitant treatment with anticoagulant drugs (VKA, LMWH, DOAC)\n* Any contraindications for DOAC administration\n* Inability to give informed consent",{"count":537,"type":22},40,[141],"The goal of this clinical trial is to investigate pharmacokinetics and pharmacodynamics of direct oral anticoagulant drugs (DOAC), specifically apixaban and edoxaban, in patients with Child A or B liver cirrhosis (LC). The primary objective of this study is to verify the ability of apixaban and edoxaban to decrease in vivo thrombin generation in LC patients.\n\nParticipants will be randomly assigned to either apixaban (Eliquis®) or edoxaban (Lixiana®) at a therapeutic dosage for 7 consecutive days.\n\nThe results of this investigation will contribute to designing a prospective multicentre interventional study to investigate the efficacy of DOAC to improve clinical outcomes in patients with LC",[541],"Liver Cirrhosis",[543,544,545,546],"Cirrhosis","DOAC","Thrombin generation","Anticoagulation","2025-02-11",{"date":549,"type":41},"2025-02-13",{"date":551,"type":41},"2024-01-18",{"date":43,"type":22},{"name":47,"class":48},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":197,"sex":18,"minAge":562,"maxAge":563,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":49},"100579156","school-based-physical-education-in-bhutan-for-physical-fitness-and-socio-emotional-competencies-in-adolescents-100579156","NCT06820632","School-based Physical Education in Bhutan for Physical Fitness and Socio-emotional Competencies in Adolescents","From Classrooms to Playgrounds in Bhutan: Evaluating the Role of School-based Physical Education on Physical Fitness, Socio-emotional Competencies and Well-being in Young Adolescents","ActiveClass-BH","Inclusion Criteria:\n\n* Enrolment in participating schools: Students must be enrolled in upper primary school classes (grades 7 and 8) in one of the three participating school.\n* Regular school attendance: Students must attend school regularly to ensure consistent exposure to the intervention (min 80% of the courses).\n* Parental consent: Written informed consent from a parent or guardian.\n* Verbal assent from the child, indicating their willingness to participate.\n\nExclusion Criteria:\n\n* Inability to participate in physical education courses: Students unable to participate in physical education classes due to medical or other significant reasons.","12 Years","14 Years",{"count":565,"type":22},360,[25],"Despite global evidence supporting the benefits of PE in promoting socio-emotional skills, much of the research has focused on countries where PE is a mandatory part of the curriculum. In contrast, Bhutan's Health and Physical Education (HPE) program is limited, with many schools lacking a structured curriculum and dedicated PE educators. This project aims to evaluate the impact of an enhanced school-based physical education (PE) program on physical fitness, socio-emotional competencies, and well-being among upper primary school students in Bhutan.\n\nThis project is a methodological collaboration between the Centre Hospitalier Universitaire Vaudois in Switzerland and the Paro College of Education and Royal Thimphu College in Bhutan.\n\nTwo public urban schools will be randomly assigned to either the \"enhanced physical education program\" or \"standard curriculum\" condition. An additional \"control school\", with no physical education, will be included in the study but not in the randomisation process for feasibility concern. A total of 360 young adolescents (120 per school, aged 12-14) will be enrolled. Baseline data on individual characteristics such as age, gender, and socio-economic status will be collected through self- and parent-reported questionnaires. Primary outcome measures include physical fitness assessed by PE teachers using various metrics, as well as socio-emotional competencies and well-being evaluated through standardised self- and parent-reported questionnaires. Data will be analysed using an intention-to-treat approach.\n\nThis project offers a unique opportunity to explore the international impact of PE within Bhutan's socio-cultural context.",[569],"School-based Intervention",[571,572,573,574,575],"physical education","adolescence","socio-emotional competencies","well-being","bhutan","2025-02-05",{"date":547,"type":41},{"date":579,"type":22},"2025-02-10",{"date":581,"type":22},"2025-08-31",{"name":47,"class":48},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":593,"conditions":594,"keywords":597,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":49},"100562481","computerized-cognitive-rehabilitation-of-patients-with-cognitive-deficits-due-to-the-human-immunodeficiency-virus-100562481","NCT06603727","Computerized Cognitive Rehabilitation of Patients With Cognitive Deficits Due to the Human Immunodeficiency Virus","Combined Cognitive and Physical Training for the Neurorehabilitation of Patients With Cognitive Deficits Due to the Human Immunodeficiency Virus: a Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of an HIV infection\n* Undetectable HIV load in the serum (\\\u003C50 copies\u002FmL) over the last 6 months prior to study inclusion.\n* Z-score ≤ -1.0 in at least one of the three following tests:\n\n  * Color Trail Test (CTT) Flexibility Index\n  * subtest Code of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV)\n  * subtest Digit Span of the WAIS-IV\n* Z-score ≤ -1.0 in at least one of the following tests:\n\n  * Symbol Digits Modalities Test (SDMT)\n  * Brief Visuospatial Memory Test Revised (BVMT-R)\n  * CTT Flexibility Index\n  * Stroop Color-Word interference test\n\nExclusion Criteria:\n\n* Clinically defined cause for cognitive deficits other than HIV\n* Diagnosis of severe depression according to a cut-off score of ≥ 27 of the Center for epidemiological studies - depression questionnaire (CES-D; Metral et al., 2020; Radloff, 1977)\n* Diagnosis of HIV-associated dementia according to the Frascati Critera (Antinori et al., 2007)\n* Current psychotic symptoms according to the Mini-International Neuropsychiatric Interview (M.I.N.I. - L, Sheehan et al., 1998) subscale of psychotic symptoms\n* Antidepressive, anxiolytic or cART medication that has been changed over the last month\n* Thoracic pain and\u002For heart palpitations at rest, during or following a physical effort (based on self-report)\n* For patients without known and clinically stable cardio-vascular disease: abnormal rest electrocardiogram readings suggestive of second degree type Mobitz or third degree atrioventricular blocking, pathological repolarization (T-wave inversion, ST elevation, abnormal QT lengthening in at least two corresponding leads), or typical features of channelopathies\n* Premature termination of maximal effort test due to cardiac problems\n* Falls in the past 12 weeks as evaluated in the enrolment interview (Hopkins Falls Grading Scale, Grade \\>1)\n* High risk of falling according a cutoff score \\> 15 sec in the Four Square Step Test (Dite \\& Temple, 2002)\n* Incapacity to discriminate colors or insufficient visual acuity that cannot be corrected\n* Incapacity or unwillingness to provide informed consent\n* Insufficient knowledge of French to understand and follow instructions",{"count":591,"type":22},24,[25],"WHO: 24 participants with cognitive deficits due to a Human Immunodeficiency Virus (HIV) infection, able to engage in moderate physical activity.\n\nWHY: The Human Immunodeficiency Virus is known to cause deficits in cognitive function, even under effective pharmacological viral load suppression. Cognitive dysfunction in patients with HIV is frequent and has a detrimental impact on their everyday personal and professional life. The purpose of this study is to evaluate two sets of computerized exercises combining cognitive and physical effort to see if they can improve executive function in patients with an HIV infection.\n\nWHAT: Study participants first undergo cognitive and physical assessments. Additional questionnaires will assess mood, everyday life cognition, function and quality. This will be followed by a 6 week training period with 2 training sessions a week. The effect of the physical and cognitive training will be measured in a post-training evaluation session. Six months after completion of the training, the study will evaluate cognitive and physical abilities of participants to study long-term effects of the respective training program.\n\nWHERE: Both the evaluation and the training sessions will be conducted on the premises of the Lausanne University Hospital (Rue du Bugnon 46, 1005 Lausanne, Switzerland)",[595,596],"Human Immunodeficiency Virus","Cognitive Dysfunction",[598,599,600,601,602,603,604,605,606],"HIV Infections","Communicable Diseases","Neurological Rehabilitation","Cognitive Behavioural Therapy","Exercise Therapy","Nervous System Diseases","Neurocognitive Disorders","Cognition Disorders","Mental Disorders","2024-09-16",{"date":609,"type":41},"2024-09-19",{"date":611,"type":22},"2024-10-01",{"date":613,"type":22},"2026-08-31",{"name":47,"class":48},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":625,"conditions":626,"keywords":630,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":49},"100540517","pericapsular-nerve-block-versus-intrathecal-morphine-for-analgesia-after-primary-hip-arthroplasty-100540517","NCT06317870","Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty","Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty: a Double Blind, Non-inferiority Study","PENGIT","Inclusion Criteria:\n\n* Male and female patients\n* ASA (American Society of Anaesthesiologists) I-III\n* 18 years of age or older\n* Patients scheduled for elective primary hip arthroplasty\n* Able to give written conformed consent autonomously\n\nExclusion Criteria:\n\n* Refusal or inability to give consent\n* Allergy to any of: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine, ondansetron or dexamethasone\n* Bleeding diathesis\n* Neurological deficit of the operative side\n* Existing preoperative opioid use\n* Renal insufficiency (GFR\\\u003C30ml\u002Fmin according to the Cockroft-Gault formula)\n* Hepatic insufficiency\n* Pregnant or lactating women",{"count":271,"type":22},[25],"The aim of this clinical trial is to compare the analgesic effect of pericapsular nerve block (PENG) with intrathecal morphine in patients scheduled for total hip replacement surgery. The main question to be answered is whether the PENG block is equivalent to intrathecal morphine in reducing postoperative pain.\n\nParticipants will be randomised into two groups. Patients assigned to the PENG group will receive spinal anaesthesia with local anaesthetic (isobaric bupivacaine) alone and a PENG block. Patients assigned to the intrathecal morphine (ITM) group will receive spinal anaesthesia with a mixture of local anaesthetic (isobaric bupivacaine) and morphine (100 mcg) and a sham PENG block to ensure patient blinding.",[627,628,629],"Analgesia","Hip Arthropathy","Post Operative Pain",[439,631,33,632],"intrathecal morphine","hip arthroplasty","2024-08-20",{"date":635,"type":41},"2024-08-22",{"date":637,"type":22},"2024-09-10",{"date":639,"type":22},"2027-05-01",{"name":47,"class":48},{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":23,"phases":649,"briefSummary":650,"conditions":651,"keywords":653,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":49},"100452294","computerized-cognitive-rehabilitation-of-executive-deficits-in-stroke-patients-100452294","NCT05169632","Computerized Cognitive Rehabilitation of Executive Deficits in Stroke Patients","Combined Cognitive and Physical Training for the Neurorehabilitation of Executive Deficits After Stroke: an Exploratory Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ischemic or haemorrhagic cerebral stroke ≥ 8 weeks before study inclusion\n* Cognitive complaint and\u002For clinical impression of dysexecutive syndrome\n* Z-Score \\\u003C -1.0 in at least two of the following domains\n\n  * Cognitive flexibility (Trail-Making Test B\u002FA)\n  * Cognitive interference (Stroop color word interference task)\n  * Divided attention (TAP divided attention)\n  * Working memory (TAP working memory, Forward Digit Span, Backward Digit Span)\n  * Design fluency (Five-points test)\n\nExclusion Criteria:\n\n* Major neurocognitive disorder according to the DSM-5\n* Proximal extremity paresis grade \\\u003C M4 on the Medical Research Council (MRC) Scale for Muscle Strength in at least one of four extremities\n* Insufficient visual acuity, visual field or hemispatial attention to engage in the training\n* Inability to discriminate colour: \\\u003C 12 points on the Ishihara test\n* Changes over the last 4 weeks in antidepressive, anxiolytic or in acetylcholinesterase inhibitor drugs\n* Thoracic pain and\u002For heart palpitations at rest, during or following a physical effort (based on self-report)\n* Clinically unstable cardio-vascular disease\n* Falls in the past 12 weeks as evaluated in the enrolment interview \\[Hopkins Falls Grading Scale (Grade \\>1)\\]\n* High risk of falling according to a score of over 15 seconds on the Four Square Step Test (FSST)\n* Insufficient knowledge or capacity of French to follow instructions\n* Incapacity or unwillingness to provide informed consent",{"count":5,"type":22},[25],"WHO: 32 participants with executive deficits related to a stroke, able to engage in moderate physical activity.\n\nWHY: Around one third of stroke patients suffer from cognitive deficits in the long term, which have a detrimental impact on everyday personal and professional life. The purpose of this study is to evaluate two sets of computerized exercises combining cognitive and physical effort to see if they can improve executive function.\n\nWHAT: Study participants first undergo cognitive and physical assessments. Additional questionnaires will assess mood, everyday life cognition, function and quality. This will be followed by a 6 week training period with 3 training sessions a week. The effect of the cognitive and physical training will be measured in a post-training evaluation session. Six months after completion of the training, the study will evaluate cognitive and physical abilities of participants to study long-term effects of the respective training program.\n\nWHERE: Both the evaluation and the training sessions will be conducted on the premises of the Centre Hospitalier Universitaire Vaudoise (Pavillon 4, Avenue de Beaumont, 1005 Lausanne, Switzerland)",[321,652],"Executive Dysfunction",[654,600,602,655,603,604,605,606,656,657,658,659,660,661],"Stroke Rehabilitation","Brain Training","Vascular System Injuries","Cerebrovascular Disorders","Multimodal Intervention","e-Health","Digital Intervention","Exergame","2024-08-12",{"date":664,"type":41},"2024-08-13",{"date":666,"type":41},"2022-03-17",{"date":668,"type":22},"2025-06-30",{"name":47,"class":48},{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":676,"eligibilityCriteria":677,"healthyVolunteers":12,"sex":18,"minAge":678,"maxAge":19,"enrollmentInfo":679,"targetDuration":4,"studyType":23,"phases":681,"briefSummary":683,"conditions":684,"keywords":686,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":700,"locationsCount":49},"100538656","phase-4-adjustment-of-antibiotic-dosage-in-pediatric-oncology-patients-with-febrile-neutropenia-and-augmented-renal-clearance-100538656","NCT06293677","Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance","Upwards Initial Adjustment of Wide-Spectrum Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Suspected Augmented Renal Clearance: A Randomized Controlled Trial With Therapeutic Drug Monitoring","DAR-ARC","Patients' inclusion criteria\n\n* Oncologic patients aged 2 months to 17 years (older than 60 days and younger than 18 years),\n* High probability of febrile neutropenia during the study period\n* Written informed consent from parents and adolescents older than 14 years\n\nPatients' exclusion criteria\n\n* Neutropenia not related to cancer and\u002For chemotherapy\n* Refusal to participate\n* Non-French speaking parents\u002Fpatients older than 11 years old\n* Absence of febrile neutropenia or agranulocytosis during the study period (secondary exclusion)\n\nFebrile neutropenia episodes inclusion criteria\n\n* Febrile neutropenia or agranulocytosis defined as:\n\n  * Neutropenia: absolute neutrophils \\<500 cells\u002FµL or agranulocytosis: absolute neutrophils \\<100 cells\u002FµL or patients expected to be neutropenic in the next 24 hours due to ongoing chemotherapy\n  * body temperature (tympanic or axillary) ≥38°C during at least one hour or a single T ≥38.5°C\n* At least 2 weeks after the end of the previous antibiotic treatment for another included episode of febrile neutropenia.\n\nFebrile neutropenia episodes exclusion criteria:\n\n* Severe renal failure (GFR\\<15 mL\u002Fmin\u002F1.73 m²)\n* Pregnancy\n* Inability to obtain the first therapeutic drug monitoring (TDM) result within 72 hours of sampling (e.g. admission before or during public holidays laboratory closure)","61 Days",{"count":680,"type":22},30,[682],"PHASE4","This clinical trial focuses on children with cancer who face infections after receiving chemotherapy. Chemotherapy affects the bone marrow, leading to a decrease in the production of certain white blood cells, particularly those that defend against bacterial infections (neutrophils). One significant concern is febrile neutropenia, where children experience a fever during a period of low white blood cell count. This condition often results from bacterial infections, necessitating prompt wide-spectrum antibiotic treatment. However, some children eliminate antibiotics in the urine too quickly during febrile neutropenia. Their kidneys function more than they normally do (renal hyperfiltration). This can lead to insufficient exposure to antibiotics to control the infection. The current standard antibiotic regimens do not account for this variable elimination rate. In this study we focus on two antibiotics used in this context: piperacillin-tazobactam and meropenem.\n\nThe main questions this study aims to answer are, in these children:\n\n* Would higher doses of antibiotics result in better blood levels of antibiotics?\n* Would they have more sides effects with higher antibiotics dosages?\n* Would they recover more quickly with higher antibiotic doses? All patients will undergo a blood test upon hospital arrival, including an assessment of renal function. If renal function is normal or diminished, the patient will receive the standard antibiotic dose. Children with increased renal function will be randomly assigned to two groups during each episode of febrile neutropenia. One group will receive standard antibiotic dosages, while the other will receive higher doses to compensate for renal hyperfiltration. Throughout the study, antibiotic levels in the blood will be monitored for all patients. This monitoring will determine if target concentrations can be achieved more quickly with experimental dosages and will allow doctors to readjust the doses if needed.",[685],"Febrile Neutropenia",[687,688,689,690,691,692,693],"Febrile neutropenia","Augmented Renal Clearance","Pediatric cancer","Therapeutic Drug monitoring TDM","Children","Wilde-spectrum antibiotic dosage","Glomerular filtration rate GFR","2024-07-10",{"date":696,"type":41},"2024-07-11",{"date":698,"type":41},"2024-03-01",{"date":386,"type":22},{"name":47,"class":48},""]